Physician profile
Amy E Suda
NPI 1588618326
$4,232.68
in general payments reported to CMS, 2019-2025
21 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $258 · 2021: $561 · 2022: $632 · 2023: $1,160 · 2024: $703 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Travel and Lodging: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.33 |
| Travel and Lodging | $522.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,148.10 | 2022-2025 | |
| Alcon Vision LLC | $636.50 | 2019-2025 | Total30, Clareon Panoptix Pro, Precision 1 |
| Bausch & Lomb Americas INC. | $389.74 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $354.48 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.16 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $231.21 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $186.02 | 2023-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Allergan, INC. | $162.49 | 2020-2022 | |
| Abb Con-Cise Optical Group LLC | $115.06 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $102.93 | 2020-2024 | Cequa |
| Lkc Technologies, INC. | $95.50 | 2023 | |
| Novartis Pharmaceuticals Corporation | $95.08 | 2019-2022 | |
| Sight Sciences, INC. | $94.60 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $91.10 | 2024-2025 | Xdemvy |
| Abbvie INC. | $85.23 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $57.19 | 2022 | |
| Kala Pharmaceuticals, INC. | $21.13 | 2022 | |
| Dompe US, INC. | $19.84 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $19.64 | 2022 | |
| Optos, INC. | $18.30 | 2020 | |
| Shire North American Group INC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Suda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.